Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07577843 · ClinicalTrials.gov registry record · Phase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
A Phase 3 study, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT07577843 is a Phase 3 study that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 460 participants.
The verdict
NCT07577843, a Phase 3 study, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).
Interventions
- DRUG Guselkumab
- DRUG JNJ-78934804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2026-05-22 |
| Est. Completion | 2030-07-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07577843
The ClinicalTrials.gov registry entry for NCT07577843 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Guselkumab is the first listed.
NCT07577843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07577843 about?
NCT07577843 is a clinical study titled "A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease". The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intest...
What is the current status of trial NCT07577843?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2026-05-22. Estimated completion is 2030-07-12.
What interventions are being tested in trial NCT07577843?
The interventions under investigation include: Guselkumab (DRUG), JNJ-78934804 (DRUG).
Who is sponsoring clinical trial NCT07577843?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.